Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Karolinska Institutet
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07029503CT.gov Swedish Cardiac And Renal Failure Study-1 | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eplerenone (this asset) | Karolinska Institutet | P2 | CCC · 48 |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BBB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Watson Pharmaceuticals | P4 | BBB |
| Semaglutide | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Clopidogrel | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Aspirin | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Retatrutide | Eli Lilly and Company | P3 | BB |
| Cilostazol | Kyunghee University Medical Center | P4 | BB |
| Lidocaine | The First People's Hospital of Lianyungang | P4 | BB |
+42 more in the Chronic Kidney Disease cohort
Other indications for Eplerenone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | B · 60 |
| Metabolic Syndrome X | — | P4 | B · 56 |
| Hypertensive Disorder | — | P4 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eplerenone in Chronic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eplerenone-chronic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →